Title: Historical aspects of botulinum toxin used clinically: Part I: is that the right serotype?

Authors: Andy Pickett

Addresses: Toxin Science Limited, Chester Road, Wrexham, LL12 8DU, UK; Botulinum Research Center, UMASS Dartmouth, 285 Old Westport Road North, Dartmouth, MA 02747-2300, USA

Abstract: The basis of botulinum toxin use as a neuromedicine started over 40 years ago when the first serotype was chosen for key initial studies in monkeys by Alan Scott and colleagues in the USA. From that point on, the protein has been used extensively and worldwide for treatment of many clinical conditions. But much remains to be documented about the earliest times, the very beginning years when critical choices and decisions were made. This first article in a series looks at the choice of the first botulinum toxin serotype used and why that choice was made.

Keywords: botulinum toxin; historical notes; first serotype; botulism; neuromedicine.

DOI: 10.1504/TBJ.2013.055664

The Botulinum Journal, 2013 Vol.2 No.3/4, pp.176 - 178

Published online: 11 Oct 2014 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article